Cybin Inc. CYBN Archives - Page 4 of 18

FridayAug 26, 2022 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain's connectivity patterns CYBN is leading the industry in developing proprietary psychedelic-based therapeutics The company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin (NEO: CYBN) (NYSE American: CYBN) is on the leading edge of this transformation, as the clinical-stage biopharmaceutical company focuses on progressing psychedelics to therapeutics by offering a new standard of care for mental-health disorders…

ThursdayAug 25, 2022 11:10 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming H.C. Wainwright Global Investment Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the H.C. Wainwright 24th annual Global Investment Conference; the elite event is slated for Sept. 12–14, 2022. CYBN CEO Doug Drysdale will present in a virtual fireside chat during the conference. The company announced that his presentation will be available starting Sept. 12 at 7 a.m. ET. An archived copy of the presentation will also be available on Cybin’s website following the event. To view the presentation, visit https://ibn.fm/OUzui To view the full press release, visit https://ibn.fm/RQvzW About Cybin Inc. Cybin…

ThursdayAug 25, 2022 10:43 am

QualityStocksNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Announces New Strategic Collaboration, Rapid Progress on FIVE EV Crossover Program

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced a collaboration with TRE (Team Rosberg Engineering) GmbH from Germany on vehicle chassis and safety development for the Mullen FIVE EV Crossover Program. TRE, an independent tier 1 engineering supplier for several large OEMs worldwide, is highly specialized in chassis development for production and prototype vehicles. In addition, Mullen is currently working with engineering partner ARRK to finalize the structural layout for the Mullen FIVE with computer-aided engineering (“CAE”) simulation loop. “The engineering work for the FIVE continues to progress in full swing. We’ve made rapid progress thanks…

TuesdayAug 16, 2022 11:42 am

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Results of Annual Meeting of Shareholders

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM)”, today announced voting results for each of the matters presented at the company’s annual shareholders’ meeting. There were 71 shareholders represented in person or by proxy, holding 47,019,721 common shares, representing 28.3% of Cybin’s total issued and outstanding common shares as at the record date for the meeting held on Aug. 15, 2022. The announcement details voting results for each matter presented, including the appointment of Zeifmans LLP as auditor and election of directors. Each of the nominees listed in Cybin’s July 13 management information…

TuesdayAug 09, 2022 11:49 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unveils Equity Program, Releases Q1 Financial Report

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced an at-the-market equity program allowing the company to issue and sell up to $35 million of common shares. According to the announcement, the shares can be sold “from time to time” through the Neo Exchange, the NYSE American LLC or any other “marketplace” upon which the shares are listed, quoted or traded, at the prevailing market price at the time of sale. The company anticipates using any proceeds from the sales of these shares for growth opportunities and working capital initiatives. In addition, Cybin…

WednesdayAug 03, 2022 2:34 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development Program

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, has completed the acquisition of a phase 1 N,N-Dimethyltryptamine (“N,N-DMT”) study, the largest DMT study to date. The study provides key data relating to the company’s proprietary CYB004 substance with the potential to effectively treat anxiety disorders. “The phase 1 EBRX-101 study, now named CYB004-E, was acquired from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) FSE: 1XU1) through Cybin IRL Limited, Cybin’s wholly owned subsidiary… The adaptive, randomized, double-blinded, placebo-controlled, single-ascending-dose study produced notable results. According to the…

ThursdayJul 28, 2022 10:53 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate in Upcoming Canaccord Genuity Growth Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be presenting at the 42nd annual Canaccord Genuity Growth Conference; the four-day event is scheduled for Aug. 8–11, 2022, in Boston. During the conference, Cybin CEO Doug Drysdale will present a fireside chat. Drysdale’s presentation is slated for Thursday, Aug. 11, 2022, at 3:30 p.m. ET. Interested individuals are invited to watch a live webcast of the event or an archived version of the event, available on the company’s investor relations page following the live presentation. To view the live presentation, visit https://ibn.fm/ghBjR To view…

ThursdayJul 28, 2022 10:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants

Company receives FDA “may proceed” letter and investigational new drug (“IND”) application clearance Enrollment for Phase 1/2a trial has already started Upcoming trial is first time a psilocybin analog will be evaluated for MDD treatment Studies show psychedelic-based treatments may have potential to revolutionize mental healthcare, but few companies have assessed limitations of oral psilocybin In a first-ever milestone, Cybin (NEO: CYBN) (NYSE American: CYBN) received approval from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/QfXhX) to proceed with its planned phase 1/2a first in-human clinical trial and has started enrollment (https://ibn.fm/HxkKp). The study is designed to evaluate Cybin’s proprietary deuterated…

TuesdayJul 26, 2022 12:04 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Scheduled Annual Shareholder Meeting

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled its annual shareholder meeting. The company’s 2022 Annual Meeting of Shareholders will begin at 10 a.m. ET on Aug. 15, 2022; the meeting will be held virtually. According to the announcement, notice of the annual meeting and a proxy statement containing meeting details should be available approximately July 25, 2022; individuals who were shareholders of record at close of business on July 11, 2022, will have access to the information. The company noted that meeting materials will be mailed to shareholders, and the information…

MondayJul 25, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study

Data from newly acquired study could accelerate clinical development of CYBN’s CYB004 by nine months The pivotal study was designed with four primary objectives Cybin’s proprietary substance has potential to effectively treat anxiety disorders, including GAD and SAD Cybin (NEO: CYBN) (NYSE American: CYBN) has completed the acquisition of the largest dimethyltryptamine (“DMT”) study to date, a Phase 1 N,N-DMT study that provides key data relating to the company’s proprietary CYB004 substance (https://ibn.fm/2Ab0T). Information from the study is expected to help the company accelerate by up to nine months its clinical development pathway of CYB004. “With the closing of this transaction…

Site Search

Company Search

Tag: Cybin Inc. CYBN